+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 11 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the combination of vicadrostat BI 690517 and empagliflozin for adults aged 18 and older who have heart failure symptoms and a left ventricular ejection fraction LVEF of 40% or more. The study aims to find out whether taking vicadrostat with empagliflozin helps people with heart failure. This is a phase III randomized, double-blind, parallel-group trial sponsored by Boehringer Ingelheim. Participants are randomly assigned to one of two groups one group takes vicadrostat combined with empagliflozin tablets once daily, and the other group takes a placebo combined with empagliflozin tablets once daily. The study has no fixed duration participants can stay in the study as long as they benefit from treatment and can tolerate it. During the study, participants visit their doctors regularly for health checks and monitoring. Throughout the study, participants undergo regular health assessments including monitoring for any unwanted effects. Study staff may also contact participants by phone and ask them to answer questions about their well-being. The main outcome being measured is the time to the first event of cardiovascular death, hospitalization for heart failure, or urgent heart failure visit over up to 42 months. Other outcomes include symptom scores, blood pressure changes, and kidney function. The study runs until enough data is collected to evaluate the treatments effects.

Age: 18Years +All GendersPhase 3
671 locations
I

Actively Recruiting

Researchers are investigating the impact of psychological guidance on patients with neuroticism who have undergone surgery for proximal humerus fractures. The study focuses on whether adding focused cognitive behavioral therapy to standard care can improve functional outcomes, reduce pain and anxiety, and enhance overall health. Mental vulnerability related to neuroticism has been linked to poorer health outcomes, and this trial aims to address this gap by providing psychological support. Participants are randomly assigned to one of two groups one receiving standard postoperative care including surgery, pain management, outpatient visits, and physical therapy the other receiving the same standard care plus eight sessions of psychological guidance over six months. The therapy sessions include psychoeducation, relaxation techniques, coping strategies, and are delivered by licensed psychologists either in-person or via videocall. During the study, participants will be assessed at 3, 6, and 12 months after surgery using various measures including the Constant Shoulder Score, Oxford Shoulder Score, pain levels, range of motion, psychological factors like anxiety and resilience, and general health. Safety monitoring includes tracking adverse events throughout the follow-up period. The total participation duration spans one year with multiple evaluations to monitor recovery and psychological changes.

Age: 18Years +All GendersPhase Not Applicable
4 locations
D

Actively Recruiting

Researchers are evaluating chemotherapy dosing strategies in older patients aged 70 years and above who have metastatic colorectal cancer and are eligible for first-line palliative chemotherapy. This phase III randomized controlled trial aims to compare upfront dose-reduced chemotherapy with standard full-dose chemotherapy, focusing on progression-free survival PFS. Patients are assessed using the Geriatric 8 G8 questionnaire to determine their risk of chemotherapy toxicity, which guides treatment assignment. The study seeks to balance treatment effectiveness with minimizing toxicity, hospital admissions, and maintaining quality of life QoL and physical functioning. Participants classified as low risk for toxicity G8 score 15 or higher are randomized to receive either doublet chemotherapy a fluoropyrimidine combined with oxaliplatin at full dose or with a 25% dose reduction upfront. Those at high risk G8 score 14 or lower or judged high risk by their oncologist receive fluoropyrimidine monotherapy either at full dose or with a 25% dose reduction. The study also allows the addition of targeted treatments like bevacizumab or EGFR inhibitors. Dose adjustments are made for patients with moderate kidney impairment. Chemotherapy is given orally or intravenously on schedules varying between every two and three weeks, depending on the regimen. Participants will be closely monitored throughout treatment, with assessments including radiological or clinical evaluations for disease progression, quality of life and physical functioning questionnaires at 1, 3, 6, and 12 months, and tracking of chemotherapy toxicity, overall survival, treatment cycles, dose changes, hospital admissions, and cumulative drug dosage. Safety and cost-effectiveness will also be evaluated over an average study duration of eight months and up to one year for some outcomes. The study plans to include 587 patients and will continue until December 2028.

Age: 70Years +All GendersPhase 3
36 locations
S

Actively Recruiting

Researchers are investigating whether taking breaks from the standard combination therapy of daratumumab, lenalidomide, and dexamethasone Dara-Rd for newly diagnosed multiple myeloma patients affects survival and quality of life. This study aims to compare continuous treatment versus planned treatment-free intervals to see if stopping therapy temporarily may reduce side effects, allow recovery from toxicity, and improve overall well-being while controlling the disease. Participants who have completed 12 cycles of Dara-Rd with at least a partial response and no signs of disease progression will be randomly assigned to one of two groups. One group will continue Dara-Rd therapy without interruption until disease progression, while the other group will stop treatment temporarily and restart it at biochemical progression, continuing until disease progression. The trial is open-label and will follow patients for several years to assess outcomes. Throughout the study, researchers will monitor participants event-free survival and progression-free survival for up to about 57 and 69 months, respectively. Additional assessments include side effect burden, patient-reported quality of life, treatment costs, treatment-free interval length, response times, and survival after second-line therapy. Regular evaluations will help determine how treatment interruption affects toxicity, dose intensity, and overall treatment outcomes over the long term.

Age: 18Years +All GendersPhase 3
38 locations
S

Actively Recruiting

Researchers are comparing robot-assisted radical prostatectomy RARP and external beam radiotherapy EBRT, sometimes combined with androgen deprivation therapy ADT, for men with high-risk non-metastatic prostate cancer. The study aims to understand differences in quality of life, functional outcomes, cost-effectiveness, progression-free survival, and distant metastasis-free survival. There is currently no clear consensus on which treatment is better, leading to variation in hospital practices. Participants will receive either RARP, which may include pelvic lymph node dissection and possibly adjuvant radiotherapy or androgen deprivation therapy, or EBRT delivered at an effective radiation dose, possibly combined with a brachytherapy boost and pelvic lymph node dissection. Positive lymph node findings will not exclude participants and may be treated with lymph node irradiation. Treatment details vary based on clinical decisions. During the study, participants will be followed for up to five years, with key assessments at three years including health-related quality of life and functional outcomes. Cost-effectiveness will also be evaluated at three years, while progression-free and distant metastasis-free survival will be tracked up to five years. The study involves regular monitoring to gather these outcomes and support shared decision-making for future patients.

Age: 50Years - 75YearsMALE
28 locations
E

Actively Recruiting

Pelvic fragility fractures in elderly patients often lead to serious health problems and high death rates. Currently, treatment approaches vary widely due to the lack of a standard protocol. This trial evaluates a new clinical pathway based on evidence and expert experience, aiming to improve outcomes for this vulnerable group who face multiple risks for poor recovery. The study compares the usual care with an evidence-based clinical pathway designed to guide diagnosis and treatment strategies. Patients will be randomly assigned to either continue with standard care or follow this best-practice clinical pathway. The pathway focuses on early diagnosis and minimally invasive treatments tailored for fragile patients. Participants will be monitored over time to assess their mobility, daily function, quality of life, pain levels, medication use, complication rates, and mortality. Assessments use tools like the Parker mobility score, Elderly mobility scale, Katz Index, EuroQol quality of life questionnaire, and pain rating scales. Follow-ups occur at multiple intervals up to two years, with careful tracking of recovery and any additional injuries or complications.

Age: 50Years +All GendersPhase Not Applicable
8 locations
E

Actively Recruiting

This research focuses on complicated appendicitis CA, a severe form of appendicitis involving gangrenous or perforated tissue andor abscess formation, which remains a common cause of emergency surgery. Despite laparoscopic appendectomy being the preferred surgical treatment and the use of postoperative intravenous antibiotics, the occurrence of intra-abdominal abscesses IAA remains significant, affecting up to 24% of patients and causing readmissions, prolonged hospital stays, and increased healthcare costs. The study aims to assess whether laparoscopic antibiotic peritoneal lavage can reduce the incidence of IAA in patients with CA. Participants undergo laparoscopic appendectomy for confirmed complicated appendicitis and are randomly assigned to receive either a laparoscopic antibiotic peritoneal lavage using a gentamicinclindamycin solution for 3 minutes after surgery or no additional intervention. This randomized, double-blind trial compares these two approaches to determine the effect of the antibiotic lavage on infection control following surgery. During the study, patients are monitored for up to 30 days to track the occurrence of intra-abdominal abscesses as the primary outcome. Secondary assessments include wound infections, treatments required for abscesses, microbial cultures, operating time, readmission and reoperation rates, length of hospital stay, adverse events, surgical complications, mortality, quality of life, postoperative consultations, and healthcare costs over a 90-day follow-up period. The study provides detailed tracking of clinical outcomes to evaluate the impact of antibiotic lavage on recovery and complications after surgery.

Age: 8Years +All GendersPhase 3
11 locations
E

Actively Recruiting

Researchers are evaluating maridebart cafraglutide as an additional treatment to standard care to reduce heart failure events, cardiovascular deaths, and improve symptoms in adults with heart failure who have preserved or mildly reduced ejection fraction and obesity. This phase 3 global trial includes a double-blind period followed by an open-label extension. The study will continue until approximately 850 primary endpoint events have occurred, focusing on serious heart failure outcomes. Participants will be randomly assigned to receive either maridebart cafraglutide or a placebo, both given by subcutaneous injection. The trial includes two parts an initial double-blind phase where neither participants nor researchers know the assigned treatment, followed by an open-label extension where all participants may receive the active drug. This design helps assess the drugs impact on heart failure and related cardiovascular events. During the study, participants will undergo regular assessments including questionnaires to measure heart failure symptoms and quality of life, blood tests for kidney function, blood sugar, cholesterol, and inflammation markers, as well as monitoring of heart failure events and mortality. The main outcome is the time until cardiovascular death or heart failure events over about 35 months. Safety and other health measures will also be tracked throughout the trial, which lasts up to about three years.

Age: 18Years - 99YearsAll GendersPhase 3
686 locations
P

Actively Recruiting

Researchers are investigating how various factors beyond tumor stage, such as biochemical, histopathological, genomic, environmental, and clinical characteristics, affect the outcomes of patients diagnosed with colorectal cancer CRC, small bowel cancer, and anal cancer. This observational study aims to collect detailed information from diagnosis through long-term follow-up to better understand prognosis and treatment effects in both early and late-stage cancers. The study addresses the gap between clinical trial populations and real-world patients by including a broader patient group treated in general practice. Participants will be followed prospectively from their initial diagnosis until death. Data collection includes medical history, clinical parameters, imaging, pathology, tumor details, treatments, hospital stays, interventions, and adverse events. With separate consent, patient-reported quality of life and work ability information will also be gathered. Additionally, biological samples obtained during routine care may be collected for further observational and molecular research. This cohort serves as a platform for evaluating new interventions through a Trials within Cohorts TwiCs design. Throughout up to ten years of follow-up, participants will undergo assessments of progression-free survival, disease-free survival, overall survival, and serious adverse events. Quality of life and work ability are assessed at intervals of 3, 6, 12, 24, 36, and 48 months. This extensive data collection supports a wide range of research aims including prognostic studies, molecular analyses, comparisons of new treatments, and health policy evaluations. The study provides a comprehensive view of treatment outcomes and patient experiences in everyday clinical settings.

Age: 18Years +All Genders
70 locations
S

Actively Recruiting

This research investigates a treatment approach for low-risk breast cancer in female patients aged 50 and above. The study evaluates the effects of a single-dose preoperative partial breast radiotherapy guided by MRI, aiming to measure the rate of complete tumor disappearance at the time of surgery, which occurs between six and twelve months after radiotherapy. Researchers will also monitor tumor response through MRI scans and blood and tumor tissue markers to predict this outcome. Patients receive a single dose of radiotherapy targeting the tumor area, with doses of 20Gy to the gross tumor volume and 15Gy to the clinical tumor volume. Surgery to conserve the breast is planned around 12 months after radiotherapy if MRI shows a complete response. If MRI indicates an incomplete response or disease progression, surgery may be moved earlier, around six months or sooner. During the months between radiotherapy and surgery, MRI scans occur every three months to monitor tumor response. Participants will be assessed regularly using MRI scans and various blood and tissue tests to follow tumor changes and treatment effects. After surgery, patients will be followed for up to 10 years to evaluate cancer outcomes, side effects, cosmetic results, and quality of life. The primary measure is the complete pathological response at 12 months post-radiotherapy, with secondary measures including radiologic response, adverse events, quality of life, cosmetic outcomes, recurrence rates, survival, and biomarkers related to radiotherapy effects.

Age: 40Years +FEMALEPhase Not Applicable
7 locations

1-10 of 11

1